Want to see NL:DSFIR full AI Analyst Report?
DSFIR Stock Chart & Stats
€91.70
€0.44(0.54%)
At close: 4:00 PM EDT
€91.70
€0.44(0.54%)
Day’s Range― - ―
52-Week Range€55.22 - €99.40
Previous CloseN/A
Volume541.35K
Average Volume (3M)706.20K
Market Cap
€23.47B
Enterprise Value€25.37K
Total Cash (Recent Filing)€2.31B
Total Debt (Recent Filing)€6.76B
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Feb 18, 2027EPS Estimate
1.48Next Dividend Ex-DateN/A
Dividend Yield2.55%
Share Statistics
EPS (TTM)-4.82
Shares Outstanding253,626,950
10 Day Avg. Volume935,459
30 Day Avg. Volume706,196
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.98
Price to Sales (P/S)1.97
P/FCF Ratio28.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€91.44Price Target Upside-0.28% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)3.67
Revenue Forecast (FY)€9.27B
Bulls Say, Bears Say
Bulls Say
Revenue Rebound And Gross-margin ImprovementThe strong revenue rebound indicates improving demand or customer volumes, while higher gross margin suggests better pricing, product mix, or cost control. Together, these trends can strengthen the economics of DSM-Firmenich’s specialty solutions and support reinvestment over the next several quarters.
Positive Operating And Free Cash FlowPositive free cash flow despite reported net losses demonstrates that the business is currently converting operations into cash. This supports investment, debt servicing, and customer innovation while giving management flexibility to navigate uneven profitability and fund longer-term growth priorities.
Differentiated Recurring B2B SolutionsDSM-Firmenich’s model combines science-based formulations, application expertise, and recurring purchasing across food, nutrition, fragrance, beauty, and animal-health markets. Embedding ingredients in customers’ products can deepen relationships and make demand more durable than transactional commodity sales.
Bears Say
Persistent Net Losses And Negative ReturnsSustained net losses and negative ROE show that improved revenue and gross margin have not yet translated into shareholder earnings. This weakens confidence in profit durability, limits internal capital generation from earnings, and leaves future performance dependent on a successful recovery in operating profitability.
Volatile And Weakening Operating ProfitabilityThe shift from profits in 2023–2024 to losses in 2025 and the TTM period indicates an unstable earnings profile. The lower EBIT margin also suggests that gross-margin gains are not fully flowing through the income statement, creating uncertainty about the sustainability of future earnings improvement.
Rising Leverage With Moderate Debt CoverageLeverage remains manageable but has risen from prior years, increasing the balance sheet’s sensitivity to prolonged weak earnings. Operating cash flow provides meaningful support, yet coverage is not especially high relative to total debt, which could constrain financial flexibility if losses persist.
DSM-Firmenich AG News
DSFIR FAQ
What was DSM-Firmenich AG’s price range in the past 12 months?
DSM-Firmenich AG lowest stock price was €55.22 and its highest was €99.40 in the past 12 months.
What is DSM-Firmenich AG’s market cap?
DSM-Firmenich AG’s market cap is €23.47B.
When is DSM-Firmenich AG’s upcoming earnings report date?
DSM-Firmenich AG’s upcoming earnings report date is Feb 18, 2027 which is in 140 days.
How were DSM-Firmenich AG’s earnings last quarter?
DSM-Firmenich AG released its earnings results on Jul 30, 2026. The company reported €0.88 earnings per share for the quarter, missing the consensus estimate of €0.893 by -€0.013.
Is DSM-Firmenich AG overvalued?
According to Wall Street analysts DSM-Firmenich AG’s price is currently Overvalued.
Does DSM-Firmenich AG pay dividends?
DSM-Firmenich AG pays a Annually dividend of €2.5 which represents an annual dividend yield of 2.55%. See more information on DSM-Firmenich AG dividends here
What is DSM-Firmenich AG’s EPS estimate?
DSM-Firmenich AG’s EPS estimate is 1.48.
How many shares outstanding does DSM-Firmenich AG have?
DSM-Firmenich AG has 253,626,950 shares outstanding.
What happened to DSM-Firmenich AG’s price movement after its last earnings report?
DSM-Firmenich AG reported an EPS of €0.88 in its last earnings report, missing expectations of €0.893. Following the earnings report the stock price went up 11.657%.
Which hedge fund is a major shareholder of DSM-Firmenich AG?
Currently, no hedge funds are holding shares in NL:DSFIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. The Animal Nutrition & Health segment offers animal proteins, vitamins, performance solutions, and data-driven precision services. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.
DSFIR Stock 12 Month Forecast
Average Price Target
€91.44
▼(-0.28% Downside)